These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 1875355)
1. 3-(5-Alkyl-4-hydroxy-3-methoxy-1-naphthalenyl)-2-methyl-2-propenoic acids as orally active inhibitors of IL-1 generation. Tanaka M; Chiba K; Okita M; Kaneko T; Tagami K; Hibi S; Okamoto Y; Shirota H; Goto M; Sakurai H J Med Chem; 1991 Aug; 34(8):2647-9. PubMed ID: 1875355 [No Abstract] [Full Text] [Related]
2. A novel orally active inhibitor of IL-1 generation: synthesis and structure-activity relationships of 3-(4-hydroxy-1-naphthalenyl)-2-propenoic acid derivatives. Tanaka M; Chiba K; Okita M; Kaneko T; Tagami K; Hibi S; Okamoto Y; Shirota H; Goto M; Obaishi H J Med Chem; 1992 Dec; 35(25):4665-75. PubMed ID: 1469696 [TBL] [Abstract][Full Text] [Related]
3. A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes. Goto M; Chiba K; Hashida R; Shirota H Agents Actions Suppl; 1991; 32():225-9. PubMed ID: 2069091 [TBL] [Abstract][Full Text] [Related]
4. Antiinflammatory properties of E5090, a novel orally active inhibitor of IL-1 generation. Shirota H; Chiba K; Goto M; Hashida R; Ono H Agents Actions Suppl; 1991; 32():219-23. PubMed ID: 2069090 [TBL] [Abstract][Full Text] [Related]
5. A novel inhibitor of IL-1 generation, E5090: in vivo inhibitory effect on the generation of IL-1-like factor and on granuloma formation in an air-pouch model. Chiba K; Goto M; Shirota H Agents Actions Suppl; 1991; 32():231-5. PubMed ID: 2069092 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of a new antiarthritic agent, IX 207-887. Mackenzie AR; Bollinger P; Cooper PH; Del Pozo E; Elford P; Graeber M; Gubler HU; Leutwiler A; Payne T; Ruch W Br J Rheumatol; 1991; 30 Suppl 2():75-8. PubMed ID: 1899626 [No Abstract] [Full Text] [Related]
8. Pharmacological modulation of rat monocytes: in vivo effects on Ia expression and interleukin-1 production. Schenkelaars EJ; Singh HN; Goldberg RL; Doughty JR; Peppard J; DiPasquale G; Quagliata F Agents Actions; 1991 Sep; 34(1-2):66-9. PubMed ID: 1793054 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of E-5110 on interleukin-1 generation from human monocytes. Shirota H; Goto M; Hashida R; Yamatsu I; Katayama K Agents Actions; 1989 Jun; 27(3-4):322-4. PubMed ID: 2801317 [TBL] [Abstract][Full Text] [Related]
10. Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. Yamamoto N; Sakai F; Yamazaki H; Kawai Y; Nakahara K; Okuhara M J Rheumatol; 1996 Oct; 23(10):1778-83. PubMed ID: 8895158 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain. Chan WK; Huang FC; Morrissette MM; Warus JD; Moriarty KJ; Galemmo RA; Dankulich WD; Poli G; Sutherland CA J Med Chem; 1996 Sep; 39(19):3756-68. PubMed ID: 8809164 [TBL] [Abstract][Full Text] [Related]
12. Comparative effects of tetrandrine and berbamine on production of the inflammatory cytokines interleukin-1 and tumor necrosis factor. Seow WK; Ferrante A; Summors A; Thong YH Life Sci; 1992; 50(8):PL53-8. PubMed ID: 1310515 [TBL] [Abstract][Full Text] [Related]
13. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. Mewshaw RE; Edsall RJ; Yang C; Manas ES; Xu ZB; Henderson RA; Keith JC; Harris HA J Med Chem; 2005 Jun; 48(12):3953-79. PubMed ID: 15943471 [TBL] [Abstract][Full Text] [Related]
15. beta-Carotene reduces paw swelling in the rat adjuvant arthritis model, while increasing IL-1 production in peritoneal macrophages. Bachmann H; Nemzek R; Coffey JW Ann N Y Acad Sci; 1993 Dec; 691():270-3. PubMed ID: 8129309 [No Abstract] [Full Text] [Related]
16. Gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, blocks amplification of IL-1 beta production by human monocytes. Furse RK; Rossetti RG; Zurier RB J Immunol; 2001 Jul; 167(1):490-6. PubMed ID: 11418687 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and quantitative structure-activity relationships of diclofenac analogues. Moser P; Sallmann A; Wiesenberg I J Med Chem; 1990 Sep; 33(9):2358-68. PubMed ID: 2118185 [TBL] [Abstract][Full Text] [Related]
18. Effect of a benzylidene derivative, a novel antirheumatic agent, on IL-1 production. Watanabe K; Hayashi H; Mori Y Pharmacol Res; 1993; 28(1):59-72. PubMed ID: 8234146 [TBL] [Abstract][Full Text] [Related]
19. IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. Fiorucci S; Santucci L; Cirino G; Mencarelli A; Familiari L; Soldato PD; Morelli A J Immunol; 2000 Nov; 165(9):5245-54. PubMed ID: 11046058 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 4,6-diethyl-1,3,4,5-tetrahydropyrano[4,3-b]indole-4-acetic acid, an isomer of etodolac. Hughes P; DeVirgilio J; Humber LG; Chau T; Weichman B; Neuman G J Med Chem; 1989 Sep; 32(9):2134-7. PubMed ID: 2527995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]